1. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
by Maximilian Merz, Anna Jauch, Thomas Hielscher, Tilmann Bochtler, Stefan Olaf Schönland, Anja Seckinger, Dirk Hose, Uta Bertsch, Kai Neben, Marc Steffen Raab, Jens Hillengass, Hans Salwender, Igor Wolfgang Blau, Hans-Walter Lindemann, Ingo G. H. Schmidt-Wolf, Christof Scheid, Mathias Haenel, Katja C. Weisel, and Hartmut Goldschmidt
BloodAdv
Volume 2(1):1-9
January 9, 2018
© 2017 by The American Society of Hematology

2. Maximilian Merz et al. Blood Adv 2018;2:1-9
© 2017 by The American Society of Hematology

3. Outcome of patients with or without high-risk aberrations.
Outcome of patients with or without high-risk aberrations. (A) +1q21: blue, no +1q21; red, subclone +1q21; green, main clone +1q21. (B) −17p: blue, no −17p; red, subclone −17p; green, main clone −17p. (C) ±MYC: blue, no ±MYC; red, subclone ± MYC; green, main clone ± MYC.
Maximilian Merz et al. Blood Adv 2018;2:1-9
© 2017 by The American Society of Hematology

4. Outcome of patients with (red) or without (blue) subclones.
Outcome of patients with (red) or without (blue) subclones. (A) Entire cohort, (B) patients with standard-risk, and (C) high-risk main clone aberration.
Maximilian Merz et al. Blood Adv 2018;2:1-9
© 2017 by The American Society of Hematology

5. Outcome of high-risk patients.
Outcome of high-risk patients. (A) Standard- and (B) high-risk patients. Bortezomib arm: purple, no subclone; red, with subclone. Thalidomide arm: green, no subclone; blue, with subclone. Colored numbers below the plots represent uncensored patients at the respective time point.
Maximilian Merz et al. Blood Adv 2018;2:1-9
© 2017 by The American Society of Hematology

6. Forest plots from univariate analysis.
Forest plots from univariate analysis. PFS (upper panel) and OS (lower panel) for the entire cohort and standard- and high-risk patients. Green, all patients; red, PAD arm; blue, VAD arm. CI, confidence interval; HR, hazard ratio; VAD, vincristine, Adriamycin, and dexamethasone.
Maximilian Merz et al. Blood Adv 2018;2:1-9
© 2017 by The American Society of Hematology